From: Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma
 | Cytoplasmic myosin VI | Nuclear myosin VI | ||
---|---|---|---|---|
 | positive | negative | positive | negative |
Tumour class (T) | Â | Â | Â | Â |
1 (n = 71) | 54 (76%) | 17 (24%) | 25 (35%) | 46 (65%) |
2 (n = 11) | 6 (55%) | 5 (45%) | 3 (27%) | 8 (73%) |
3 (n = 57) | 41 (72%) | 16 (28%) | 20 (35%) | 37 (65%) |
4 (n = 6) | 3 (50%) | 3 (50%) | 3 (50%) | 3 (50%) |
Stage | Â | Â | Â | Â |
I (n = 66) | 50 (76%) | 16 (24%) | 23 (35%) | 43 (65%) |
II (n = 11) | 6 (55%) | 5 (45%) | 3 (27%) | 8 (73%) |
III (n = 49) | 35 (71%) | 14 (29%) | 19 (39%) | 30 (61%) |
IV (n = 19) | 13 (68%) | 6 (32%) | 6 (32%) | 13 (68%) |
Grade | Â | Â | Â | Â |
I (n = 5) | 5 (100%) | 0 (0%) | 1 (20%) | 4 (80%) |
II (n = 79) | 59 (75%) | 20 (25%) | 31 (39%) | 48 (61%) |
III (n = 38) | 28 (74%) | 10 (26%) | 10 (26%) | 28 (74%) |
IV (n = 21) | 10 (48%) | 11 (52%) | 8 (38%) | 13 (62%) |
Histological subtype of RCC | Â | Â | Â | Â |
clear cell (n = 128) | 89 (70%) | 39 (30%) | 46 (36%) | 82 (64%) |
papillary (n = 10) | 9 (90%) | 1 (10%) | 2 (20%) | 8 (80%) |
chromophobic (n = 5) | 4 (80%) | 1 (20%) | 2 (40%) | 3 (60%) |
undifferentiated (n = 2) | 2 (100%) | 0 (0%) | 1 (50%) | 1 (50%) |